Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mirdametinib and Sirolimus for RAS Mutated Relapsed Refractory Multiple Myeloma
NCT06876142Phase 2Suspended
- Sponsor
- National Cancer Institute
- Start
- Nov 2026
- Primary completion
- Jan 2033
- Countries
- 1
01
Overview
A Phase 2 trial of mirdametinib in multiple myeloma (MM), sponsored by National Cancer Institute. Started Nov 2026; status: suspended.
02
Drugs
mirdametinib
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT06876142.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06876142.